76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 56-57

76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery

76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery

Background/Significance

Surgical navigation and localization advancements seek to improve surgical time, total tissue excised, and the need for
re-excision in breast surgery. Bracketed localization is frequently used for procedures localizing wide or multifocal breast tumors. Electromagnetic chip (EMC) localization via Smart Clip (Elucent Medical, Madison WI) is a novel approach to clip localization. This prospective evaluation compares EMC bracketed localization to conventional wire localization in bracketed breast conserving surgery (BCS).

Materials and Methods

A prospective, institutional review board–approved single-institution cohort of female patients with breast cancer undergoing EMC bracketed localization was compared with a contemporary cohort of patients with breast cancer undergoing wire bracketed BCS. Key variables included number of localizers placed, complete retrieval of localizers, additional margins taken intraoperatively, positive malignant margins, reoperation for positive margins, time of incision to radiograph, and specimen length (mm) and volume (cm3). Statistics were performed using Kruskal-Wallis test for numerical covariates and χ2 test or Fisher exact test, where applicable, for categorical covariates.

Results

Seventy-four subjects were included, 31 with EMC localization vs 43 wire localization; of these, 10 EMC and 4 wire localized cases were oncoplastic reductions. All cases were performed by 8 fellowship-trained breast surgeons. The mean age was 66 years (range, 36-86). Mean tumor size was 41.2 mm for EMC vs 39.5 mm for wire cases (range, 12-90). Time from incision to specimen radiograph was shorter in EMC compared with wire cases, but not statistically significant. Cases with EMC had a fewer number of positive/close (<2 mm) ductal carcinoma in situ margins (29%), compared with 50% of the wire localized cases (P <.072). Specimen length and volume were also significantly lower with EMC vs wire localization (P = .029 and P = .019, respectively). Also, 93.5% of patients who underwent EMC localization had complete retrieval of localization device in the initial specimen (P = .172). Reoperation reexcision of tumor margins was required for only 29% of the EMC localized patients (P = .185). Use of the EMC localizer was also associated with a lower complication rate (6.5% vs. 9.3%; P = 1.00).

Conclusion

In this prospective, single-institution study, EMC localization was associated with fewer positive margins and smaller resection specimens in EMC bracketed BCS compared with wire bracketed procedures.

Articles in this issue

3 Intraoperative Radiotherapy: Alive and Well in the Bronx
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast
20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast
Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.